 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, dapagliflozin/linagliptin (IN-C009) / Korea Kolmar, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
PK/PD data, Journal: Pharmacokinetics of a Fixed-Dose Combination Product of Dapagliflozin and Linagliptin and Its Comparison with Co-Administration of Individual Tablets in Healthy Humans. (Pubmed Central) - Mar 27, 2022
The results of the clinical study demonstrated comparable pharmacokinetic characteristics between IC and FCDP forms of dapagliflozin and linagliptin. The combined use of dapagliflozin and linagliptin was safe and tolerable in both formulations.
- | dapagliflozin/linagliptin (IN-C009) / Korea Kolmar
New P1 trial: The Pharmacokinetics, Safety and Tolerability of IN-C009 in Healthy Subjects (clinicaltrials.gov) - Oct 3, 2021
P1, N=48, Completed, Sponsor: Korea University Anam Hospital